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OBJECTIVES: Anemia and changes in platelets (PLT) are common in inflammatory bowel disease (IBD). In our
study, we aimed to verify whether PLT count can independently reflect the severity of IBD.
METHODS: In our hospital, 137 Crohn’s Disease (CD), 69 Ulcerative colitis (UC) patients, and 412 healthy controls
were included to compare the differences in PLT count. In addition, the effect of anemia, C-reactive protein
(CRP), age, CD activity index (CDAI) or Mayo on PLTs was also analyzed. If PLTs independently affected CD or UC,
we used the receiver operating characteristic (ROC) curve to verify the diagnostic value and obtain the cut-off
value of PLT.
RESULTS: CD and UC patients had higher PLT than controls (po0.001, po0.001; respectively). In CD patients, the
results showed that patients with anemia (Po0.01), Iron Deficiency Anemia (IDA) (po0.001), CRPX8 mg/L
(p=0.046), and CDAIX150 (po0.001) had higher PLT, while in UC patients, those with anemia (p=0.018), CRPX8
mg/L (p=0.045), and MayoX3 (p=0.029) had higher PLT. Univariate analysis showed that CDAI was positively
correlated with PLT count (po0.001), while hemoglobin (p=0.001) and age (po0.001) were negatively
correlated with PLT in CD. In UC patients, Mayo (p=0.001) and CRP (po0.001) were positively correlated with
PLT, while hemoglobin (p=0.002) was negatively correlated. Finally, by linear stepwise multivariate analysis, we
clarified the positive relationship between PLT and CD (po0.001) by eliminating the interference of
hemoglobin, and determined the cut-off value of PLT as 298 109/L. For UC, we did not obtain similar results.
CONCLUSIONS: PLT can be an indicator of disease severity in CD, while there is a lack of evidence regarding this
finding in UC.
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’ INTRODUCTION
Inflammatory bowel disease (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC), refers to a group of
chronic gastrointestinal disorders characterized by dysregu-
lated intestinal inflammation (1). The immune dysregulation
may dominate IBD pathogenesis with its active components
(2), while other factors such as genetic (3) and environmental
factors (4) have also been implicated. In addition, an increa-
sing amount of evidence has highlighted the importance of
non-immune cells and platelets (PLT) as key players in the
development of IBD (5).
The primary role of PLT is hemostasis, including surveying
the endothelial barrier consistency and interfering when vessel
integrity is threatened (6). Moreover, it has been demonstrated
that PLT have immunological properties. Through the activity
of GP VI and integrin family surface receptors, activated PLT
transform into high-affinity platforms that are suitable for
participating in inflammatory reactions (7). They also express
Toll-like receptors that can bind to lipopolysaccharides on the
outer membrane of gram(-) bacteria (8). When activated at
inflammatory sites, PLT excrete large amounts of pro-inflam-
matory substances located in their intracellular granules (9), as
well as immune-like cells even at distant sites such as PLT-
derived CD40 ligand (CD40L), to activate dendritic cells in the
injured tissue (10).
We know that patients with IBD usually have gastro-
intestinal symptoms, such as diarrhea, abdominal pain, weight
loss, or gastrointestinal bleeding. Remarkably, approximately
one-third of IBD patients present at least one extra-intestinal
feature (11). Anemia, especially microcytic hypochromic
anemia, which is the main hematological symptom, could
be perceived as a manifestation or complication of IBD.
Anemia is consistently linked with IBD and the prevalence
ranges from 4% to 67% (12,13). In IBD patients, iron defici-
ency anemia (IDA) is the most frequent manifestation of the
microcytic hypochromic anemia (14). Either chronic intest-
inal bleeding caused by mucosal damage or poor nutritionalDOI: 10.6061/clinics/2020/e1596
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status influencing the absorption of iron in the inflamed
mucosa of the duodenum and upper jejunum can result in
anemia. Iron supplementation for IBD treatment has gained
increasing attention (15).
In IBD, anemia and PLTcount changes were observed. How-
ever, no study has been conducted to determine whether there
is a close relationship between anemia and PLT in IBD.
Whether PLT count change is affected by secondary bone
marrow metabolic disorder or anemia is yet to be deter-
mined. In our study, we aimed to determine the relationship
between the three factors of IBD, PLT, and anemia by analy-
zing clinical data. In addition, we aimed to verify whether
PLT can be an independent indicator of IBD severity.
’ MATERIALS AND METHODS
Patients and diagnostic criteria
Medical records of patients undergoing evaluation and
treatment for UC and CD in our hospital between January 1,
2012, and May 1, 2016, were reviewed. This study was app-
roved by our Institutional Review Board. Informed consent
was obtained from the participants and their privacy was
respected. The experimental protocol was approved by the
Ethics Committee of the First Affiliated Hospital, College of
Medicine, Zhejiang University. In addition, all procedures
were performed in accordance with the relevant guidelines
and regulations.
In total, 137 CD patients and 69 UC patients were inclu-
ded. The diagnosis of UC and CD were made based on a
combined assessment of abdominal imaging, endoscopy,
symptomatology, and histology. The pattern and distribution
of UC and CD were obtained from endoscopic, radiological,
and histological findings (16). All the patients enrolled had
not received prior treatment with hormones, immunosup-
pressants, or biological agents. Additionally, we selected 412
healthy controls matched by gender, age, and Body Mass
Index (BMI) from an international medical center. Never-
theless, because the values of some BMI data in IBD patients
were very low, we selected the lowest BMI in the group of
controls for random matching.
The inclusion criteria were as follows: 1) age418 years old;
2) no history of tuberculosis, cirrhosis, cancer, cardiovascular
and cerebrovascular diseases, or other chronic diseases; 3) no
history of thrombus or drugs that can influence PLT quantity
and activity; 4) no other acute infectious diseases.
We extracted data, including age, gender, general con-
dition, hemoglobin (HB), PLT, C-reactive protein (CRP),
hematocrit (HCT), mean corpuscular volume (MCV), mean
corpuscular hemoglobin (MCH), and mean corpuscular
hemoglobin concentration (MCHC). Moreover, anemia was
defined as HBo120 g/L in males or o110 g/L in females.
Microcytic hypochromic anemia was defined as MCVo80 fl,
MCHo26 pg, and MCHCo310 g/L. CRP was chosen to
reflect the disease activity and 8 mg/L was the cut-off level
between remission and IBD activity (17). In addition, the CD
activity index (CDAI) was used to assess the condition of the
CD patients, while the Mayo scoring system was used
to assess the condition of the UC patients (18,19). The Mayo
scoring system (including defecating frequency, bloody
stools, endoscopic characteristics, and physician evaluation)
indicated that o3 is remission, 3-5 is mild activity, 6-10 is
moderate activity, and 11-12 is severe activity. In addition,
the CDAI indicated that o150 is remission, 150-220 is mild
activity, 221-450 is moderate activity, and 4450 is severe
activity.
Statistical analysis
Continuous variables were expressed as mean±standard
deviation. The variables were tested by SPSS and were found
to be normally distributed. Student’s t-test was used to com-
pare the difference in PLT between the different subgroups.
Univariate analysis of linear regression was performed to
compare PLT count with age, anemia, IDA, CRP, CDAI, and
Mayo. If a significant difference was found on univariate ana-
lysis, it was included into the stepwise multivariate ana-
lysis using logistic or linear regression. In addition, Pearson’s
correlation coefficient was conducted to correlate PLT and
CDAI or Mayo score. Furthermore, coefficients of variables for
the multivariate model were estimated. If PLT was related to
the severity of CD or UC, we also conducted an ROC curve to
verify the diagnostic value of PLTand to obtain the PLTcut-off
value. The PLT cut-off value was defined by Youden’s index.
The statistical significance was defined as pp0.05. We used
SPSS 21.0 (IBM, Chicago, IL, USA) to perform the statistical
analysis. Other associated data were calculated and plotted
using GraphPad Prism 5 (Graph Pad, San Diego, CA, USA).
’ RESULTS
The basic characteristics of the patients, including age,
gender, PLT, CRP, hemoglobin, CDAI or Mayo are described
in Table 1. We found that CD and UC patients had higher
PLT than the controls (294.58±103.86 vs. 208.97±50.39,
po0.001; 267.29±109.34 vs. 209.68±59.2, po0.001; respec-
tively) (Figure 1 A and B). Then, we sought to determine the
factors affecting the PLT of CD and UC. In CD patients, the
Table 1 - Basic characteristics of CD and UC Patients.
CD UC CD control UC control
Gender/male (n (%))# 73 (53.3) 38 (55.1) 146 (53.3) 76 (55.1)
Age* 36.8±12.6 48.9±15.6 35.7±11.6 49.1±15.9
PLT (10E9/L) 294.58±103.86 267.29±109.34 208.97±50.39 209.68±59.2
CDAI 124.57±61.32 - - -
Mayo - 7.01±3.16 - -
Disease activity classification (n (%))#
Remission 97 (70.8) 9 (13.0)
Mild 34 (24.8) 15 (21.7)
Moderate 6 (4.4) 33 (47.8)
Severe 0 (0) 11 (15.9)
*The age ‘‘years’’ were described as mean±standard deviation.
#Male gender and degree of disease activity were described as number (percent).
PLT: platelet; CD: Crohn’s disease; UC: ulcerative colitis; CDAI: Crohn’s disease activity index; Mayo: Mayo scoring system
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results showed that patients with anemia (323.4±107.68 vs.
248.89±78.97, po0.01; Figure 2A), IDA (345.45±101.26 vs.
270.51±96.59, po0.001; Figure 2B), CRPX8 mg/L (304.9±
104.95 vs. 263.97±100.98, p=0.046; Figure 2C), and CDAI
X150 (345.45±101.26 vs. 273.75±94.22, po0.001; Figure 2D)
had higher PLT. However, there was no significant difference
between males and females (p=0.248).
Similarly, UC patients with anemia (302.37±127.12 vs.
240.3±85.68, p=0.018; Figure 3A), CRPX8 mg/L (293.18±
117.35 vs. 240.17±96.31, p=0.045; Figure 3B), and MayoX3
(277.86±107.21 vs. 192.33±104.01, p=0.029; Figure 3C) had
higher PLT, whereas IDA (p=0.241, Figure 3D) and gender
(p=0.071) were not statistical significance.
Furthermore, we performed a univariate analysis for
the variables above. In CD patients, it showed that CDAI
was positively correlated with PLT (po0.001, Beta=0.382;
Figure 4A) and Pearson’s correlation was 0.382 (po0.001),
while hemoglobin (p=0.001, Beta=-0.282; Figure 4B) and age
(po0.001, Beta=-0.312; Figure 4C) were negatively correlated
with PLT. In addition, CRP was not statistically correlated
with PLT (p=0.207; Figure 4D). In UC patients, we found that
Mayo (p=0.001, Beta=0.391; Figure 5A) and CRP (po0.001,
Beta=0.46; Figure 5B) were positively correlated with PLT,
while hemoglobin (p=0.002, Beta=-0.374; Figure 5C) was nega-
tively correlated with PLT. Pearson’s correlation between PLT
and the Mayo score was 0.391 (p=0.001). Age had no statistical
correlation with PLT (-p=0.06; Figure 5D).
Finally, we performed a linear stepwise multivariate ana-
lysis on PLT with age, hemoglobin, CRP, CDAI or Mayo.
Firstly, through the analysis of the collinearity of the vari-
ables, we found that there was no severe collinearity among
the respective variables (VIFo10). For CD patients, we
clarified the positive relationship between PLT and CDAI
(po0.001, Beta=0.378, 95%CI: 0.395, 0.935) by eliminating the
interference of hemoglobin (P=0.006). In contrast, age was
negatively correlated with PLTs (po0.001, Beta=-0.286, 95%
CI: -3.692, -1.110). These results showed that PLT can be used
to evaluate the severity of CD. In UC patients, Mayo (p=0.005,
Beta=0.302, 95%CI: 3.334, 17.692) and CRP (p=0.002, Beta=
0.334, 95%CI: 0.383, 1.627) were still positively correlated
with PLT. Moreover, hemoglobin (p=0.006, Beta=-0.286, 95%
CI: -2.535, -0.454) was negatively correlated with PLT. For
these results, we could not clarify whether PLT change in UC
was affected by hemoglobin.
Through the ROC curve, we aimed to determine whether
PLTs had a diagnostic value for CD. CD patients were
divided into remission and activity by CDAI. The results of
the ROC curve showed that PLT had a diagnostic signifi-
cance for CD (Area=0.695, po0.001) and the PLT cut-off
value was 298 109/L.
Figure 1 - (A) CD patients had higher PLT than controls (294.58±103.86 vs. 208.97±50.39, po0.001); (B) UC patients had higher PLT
than controls (267.29±109.34 vs. 209.68±59.2, po0.001).
Figure 2 - In CD patients, it was demonstrated that patients with (A) anemia (323.4±107.68 vs. 248.89±78.97, po0.01), (B) IDA (345.45±
101.26 vs. 270.51±96.59, po0.001), (C) CRPX8 mg/L (304.9±104.95 vs. 263.97±100.98, p=0.046), (D) CDAIX150 (345.45±101.26 vs.
273.75±94.22, po0.001) had higher PLT.
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’ DISCUSSION
In our study, we found that PLT count was positively
correlated with the CDAI while it was negatively correlated
with age. In addition, we identified the diagnostic value of
PLT for CD using the ROC curve and defined the PLT cut-off
value for CD as 298*10E9/L. In UC patients, we found that
Mayo and CRP were positively correlated with PLT, while
hemoglobin was negatively correlated with PLT. However,
we could not conclude as to whether PLT can reflect the
severity of UC because the influence of hemoglobin on PLT
could not be ignored.
In CD patients, PLT was negatively correlated with age.
As individuals age, the number and function of hemato-
poietic stem cells may decrease and PLT consumption due to
vascular endothelial injury may induce a decrease in PLT.
Cowman et al. reported that aging resulted in a significant
reduction of the PLT function in the Dynamic Platelet
Function Assay (20). Destruction of platelet function may
also contribute to affect the lifetime and quantity of PLT.
Murawska et al. found that anemia coexists with IBD (15)
and our study was consistent with their results. We know
that there is an increased activation of tumor necrosis factor a
(TNF-a) in IBD (1). Moreover, Roodman et al. first reported
Figure 3 - In UC patients, (A) anemia (302.37±127.12 vs. 240.3±85.68, p=0.018), (B) CRPX8 mg/L (293.18±117.35 vs. 240.17±96.31,
p=0.045), (C) MayoX3 (277.86±107.21 vs. 192.33±104.01, p=0.029) had higher PLT. IDA (p=0.241) had no significant difference.
Figure 4 - In CD patients, it was shown that (A) CDAI was positively correlated with PLT (po0.001, Beta=0.382), while (B) hemoglobin
(p=0.001, Beta=-0.282) and (C) age (po0.001, Beta=-0.312) were negatively correlated with PLT. Moreover, (D) CRP had no significant
correlation with PLT (p=0.207).
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that TNF-a can inhibit erythropoiesis (21). Since then, more
studies have reported the relationship between TNF-a and
anemia. Some articles had reported that TNF-a indirectly
suppresses the expression of erythropoietin synthesis in
kidneys, potentially by GATA-2 and nucleus factor kappa B
overexpression (22,23). In addition, Rusten et al. found that
TNF-a can directly inhibit human erythropoiesis via TNF
receptors, including p55 and p75 TNF receptors (24). Further-
more, serving as a ligand for cellular iron efflux receptor,
hepcidin was strongly correlated with IL-6 levels in CD
patients (25).
In IBD patients, in addition to anemia, elevated PLT levels
could also be found. In our study, after excluding the effect of
anemia on PLT, we found that PLT were directly associated
with CD disease activity. Di Sabatino et al. found evidence
for enhanced in vivo 11-dehydro-thromboxane-dependent
PLT activation and lipid peroxidation in IBD patients while
demonstrating that anti-TNF-a therapy with infliximab
down-regulates isoprostane generation and TX biosynthesis
in vivo in responder IBD patients (26). Except for hemostatic
function, the innate immunological properties of PLT have
become increasingly elucidated. Youssefian et al. demon-
strated that PLT can internalize pathogens resistant to clea-
rance, such as Staphylococcus aureus or HIV virus, promoting
further PLT activation changes (27). In addition, PLT can
crosstalk, recruit, and activate leukocytes, endothelial, and
immune-like cells by excreting large amounts of pro-inflam-
matory substances located in their intracellular granules (9).
Heits et al. have shown that IBD patients have elevated
plasma thrombopoietin (TPO) and IL-6 levels, an acute phase
reactant, which can promote hepatic TPO production (28,29).
Since PLT are involved in immune responses, can platelets act
as active inflammatory components?
Collins et al. demonstrated that PLT circulate at a highly
activated state in IBD and activation possibly occurs in the
mesenteric microcirculation (30,31). During activation, PLT
can develop receptors for chemokines, cytokines, and
complement components, enabling them to participate in
various inflammatory cascades in IBD (32). Proteomic
studies have identified that more than 300 proteins accumu-
lated in the granules of activated PLT (33). For example, P-
selectin is a member of the CAMs family mainly produced in
PLT, which is also detected in patients with IBD. P-selectin
can bind to PSGL-1 in leukocytes (32). Moreover, it can also
induce tissue factor (TF) generation, stimulating the release
of PDMPs bearing TF by leukocytes (34). This may support
the evidence of P-selectin in IBD pathogenesis. In addition, as
a member of the family of CD40, sCD40L is believed to be
produced and released only by activated PLT in IBD patients.
Increased levels of CD40L(+) PLT and sCD40L are demon-
strated in IBD (35). In an animal experiment, Vowinkel et al.
found that CD40 deficient mice experienced significantly
milder dextran sodium sulfate (DSS) colitis compared to
wild-type littermates (36). These immune functions of PLT
lay the foundation for their role in IBD.
Our study demonstrated the significance of PLT as an
important indicator of inflammation in CD; however, some
limitations still exist. Firstly, the main limitation of the study
was related to the lack of endoscopic examination. The
absence of endoscopic examination data led to the inability
to understand the severity and healing of the colonic mucosa,
thereby making it impossible to combine PLT, disease activity
score, and endoscopic examination for disease assessment.
This factor also made our results less reliable. Secondly, the
PLT cut-off value for CD was 298*10E9/L in our study, which
is almost the normal upper limit of PLT. We require more cases
to improve the cut-off value. In addition, we need more data
of moderate and severe CD patients to improve the PLT
evaluation system. Second, although PLT cannot indepen-
dently reflect the severity of UC, more data is needed to
support our result. In the case of excluding anemia in UC
patients, PLTcan still be used as a reference index to reflect the
disease activity to some extent.
In conclusion, PLT can reflect the disease severity of CD,
while there is a lack of evidence regarding this finding in UC.
The higher the PLT count, the more serious the CD.
Figure 5 - In UC patients, we found that (A) Mayo (p=0.001, Beta=0.391) and (B) CRP (po0.001, Beta=0.46) were positively correlated
with PLT, while (C) hemoglobin (p=0.002, Beta=-0.374) was negatively correlated with PLT. (D) Age had no significant correlation with
PLT (p=0.06).
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Furthermore, we need more multi-center research and data
to support our results because it is possible that PLT can
reflect the severity of UC independently.
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